386 completed, 142 unknown, 110 terminated, 74 recruiting. 807 Phase 2, 137 Phase 1, 20 Phase 3.
Follow Irinotecan: new trials by email Literature Review of Irinotecan trials Research Report on Irinotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-12-31 | 2026-11-05 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer Irinotecan, Oxaliplatin, GFH276 - CRC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 150 | 2026-11-15 | 2026-11-06 |
| Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies PM54, Irinotecan, Doxorubicin - Advanced Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | PharmaMar | 231 | 2026-11-12 | 2026-09-24 |
| Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma Pembrolizumab and Irinotecan - Unresectable or Metastatic Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 46 | 2026-11-01 | 2026-09-14 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma Valproic Acid (VPA), Irinotecan, Simvastatin - Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Inova Health Care Services | 52 | 2026-09-04 | 2026-09-21 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel - Gastric Cancer Peritoneal Metastasis (GCPM) | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 40 | 2026-09-01 | 2026-08-25 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer HSK42360-Na Tablets, Cetuximab (EGFR inhibitor), mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU) - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2026-08-12 | 2026-08-27 |
| Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients Ivonescimab +mFOLFOXIRI +celecoxib - Colorectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2026-08-10 | 2026-09-09 |
| AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer AK112, Irinotecan, Cisplatin - Neuroendocrine Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 56 | 2026-08-01 | 2026-07-17 |
| Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer Abemaciclib, Oxaliplatin, Calcium Folinate - Liver Metastases From Colorectal Cancer (mCRC) | Phase 2 | Enrolling by invitation | Fudan University | 16 | 2026-07-30 | 2026-07-22 |
| Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial Cetuximab, Irinotecan, Bevacizumab - Colorectal Neoplasms Malignant, Neoplasm, Metastatic | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 160 | 2026-07-23 | 2026-09-24 |
| Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study Toripalimab, Cetuximab, Irinotecan - Colorectal Cancer (CRC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 46 | 2026-07-03 | 2026-10-27 |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab - Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan | Phase 2 / Phase 3 | Not yet recruiting | Hebei Medical University Fourth Hospital | 408 | 2026-05-20 | 2026-05-13 |
Showing 20 of 807. Sign in to see all of them.
Colorectal Neoplasms (264) · Rectal Neoplasms (98) · Colonic Neoplasms (92) · Stomach Neoplasms (69) · Pancreatic Neoplasms (64) · Neoplasm Metastasis (48) · Esophageal Neoplasms (41) · Neoplasms (39) · Lung Neoplasms (30) · Small Cell Lung Carcinoma (29) · Carcinoma, Non-Small-Cell Lung (27) · Glioblastoma (27) · Neuroblastoma (25) · Glioma (22) · Brain Neoplasms (20)
National Cancer Institute (NCI) (25) · Alliance for Clinical Trials in Oncology (24) · Memorial Sloan Kettering Cancer Center (23) · Fudan University (22) · Sun Yat-sen University (16) · SWOG Cancer Research Network (12) · M.D. Anderson Cancer Center (11) · National Cancer Center, Korea (11) · Hoffmann-La Roche (10) · Children's Oncology Group (9) · Pfizer (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · UNICANCER (9) · Eli Lilly and Company (8) · Federation Francophone de Cancerologie Digestive (8)
United States (375) · China (147) · France (79) · Canada (54) · South Korea (53) · Italy (50) · Spain (48) · Germany (44) · United Kingdom (37) · Australia (34) · Japan (27) · Belgium (23) · Denmark (20) · Taiwan (18) · Greece (14)
David H. Ilson, MD, PhD (5) · Annick Desjardins, MD, FRCPC (4) · John Souglakos, MD (4) · Se Hoon Park, MD (4) · Zhen Zhang, MD (4) · Charles R. Thomas, MD (3) · Dung Le, MD (3) · Emily Slotkin, MD (3) · John R. Murren, MD (3) · Lin Shen, Professor (3)
PMID 32816630, PMID 21561347, PMID 10334539, PMID 10615932, PMID 12187070, PMID 12196368, PMID 12467231, PMID 12794246, PMID 12794247, PMID 14769136, PMID 14769140, PMID 14998842, PMID 15083176, PMID 15565574, PMID 15641483, PMID 15668285, PMID 15709193, PMID 15865075, PMID 15865096, PMID 15895230, PMID 15908661, PMID 16062075, PMID 16096702, PMID 16170339, PMID 16200343, PMID 16399443, PMID 16446336, PMID 16514137, PMID 16533878, PMID 16601427, PMID 16777690, PMID 16863926, PMID 16865597, PMID 16873427, PMID 16943524, PMID 17065590, PMID 17227978, PMID 17264331, PMID 17317837, PMID 17545848, PMID 17553200, PMID 17592291, PMID 17785765, PMID 17805064, PMID 17968163, PMID 18083691, PMID 18172173, PMID 18182667, PMID 18417462, PMID 18484593
2023 (7), U10CA032102 (7), U10CA180886 (7), 2009 (6), 2016 (6), 2017 (6), U10CA098543 (6), U10CA180888 (6), 2025 (5), U10CA021115 (5), U10CA031946 (5), 2008 (3), P30CA006973 (3), P30CA008748 (3), P30CA022453 (3)